DNAJC24

Summary

DNAJC24 (DnaJ heat shock protein family (Hsp40) member C24, HGNC:26979) is a protein-coding gene on chromosome 11p13, encoding DnaJ homolog subfamily C member 24 (Q6P3W2). Stimulates the ATPase activity of several Hsp70-type chaperones.

Diphthamide is a unique posttranslationally modified histidine found only in translation elongation factor-2 (EEF2; MIM 130610). This modification is conserved from archaebacteria to humans and serves as the target for ADP-ribosylation and inactivation of EEF2 by diphtheria toxin (DT) and Pseudomonas exotoxin A. DPH4 is 1 of several enzymes involved in synthesis of diphthamide in EEF2 (Liu et al., 2004 [PubMed 15485916]).

Source: NCBI Gene 120526 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 36 total — 3 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 2
• MANE Select transcript: NM_181706

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26979
Approved symbol	DNAJC24
Name	DnaJ heat shock protein family (Hsp40) member C24
Location	11p13
Locus type	gene with protein product
Status	Approved
Aliases	JJJ3
Ensembl gene	ENSG00000170946
Ensembl biotype	protein_coding
OMIM	611072
Entrez	120526

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 5 nonsense_mediated_decay, 4 protein_coding_CDS_not_defined, 3 protein_coding, 1 retained_intron

ENST00000395949, ENST00000465995, ENST00000524747, ENST00000525511, ENST00000526042, ENST00000526529, ENST00000527601, ENST00000527731, ENST00000529086, ENST00000530125, ENST00000532385, ENST00000910452, ENST00000910453

RefSeq mRNA: 1 — MANE Select: NM_181706 NM_181706

CCDS: CCDS7873

Canonical transcript exons

ENST00000465995 — 5 exons

Exon	Start	End
ENSE00001916957	31430271	31432835
ENSE00003540278	31426287	31426355
ENSE00003555370	31370716	31370859
ENSE00003578437	31414811	31414949
ENSE00003849117	31369860	31369912

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 93.07.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.8566 / max 531.8351, expressed in 1758 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
113594	13.6336	1745
113593	0.9142	492
113592	0.2554	83
113595	0.0534	10

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
heart right ventricle	UBERON:0002080	93.07	gold quality
endothelial cell	CL:0000115	92.80	gold quality
Brodmann (1909) area 23	UBERON:0013554	92.30	gold quality
biceps brachii	UBERON:0001507	91.30	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	90.65	gold quality
calcaneal tendon	UBERON:0003701	90.30	gold quality
ventricular zone	UBERON:0003053	88.68	gold quality
body of pancreas	UBERON:0001150	87.91	gold quality
choroid plexus epithelium	UBERON:0003911	87.79	gold quality
CA1 field of hippocampus	UBERON:0003881	87.78	gold quality
left testis	UBERON:0004533	86.92	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	86.80	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	86.62	gold quality
skin of hip	UBERON:0001554	86.45	gold quality
buccal mucosa cell	CL:0002336	86.44	gold quality
right testis	UBERON:0004534	86.32	gold quality
nephron tubule	UBERON:0001231	86.19	gold quality
pancreas	UBERON:0001264	85.98	gold quality
islet of Langerhans	UBERON:0000006	85.59	gold quality
renal glomerulus	UBERON:0000074	85.55	gold quality
hindlimb stylopod muscle	UBERON:0004252	85.28	gold quality
testis	UBERON:0000473	85.22	gold quality
muscle of leg	UBERON:0001383	85.11	gold quality
sperm	CL:0000019	84.97	gold quality
gastrocnemius	UBERON:0001388	84.95	gold quality
secondary oocyte	CL:0000655	84.88	gold quality
middle temporal gyrus	UBERON:0002771	84.84	gold quality
cranial nerve II	UBERON:0000941	84.75	gold quality
primary visual cortex	UBERON:0002436	84.68	gold quality
muscle organ	UBERON:0001630	84.61	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-9388	yes	6.53
E-ANND-3	yes	5.78

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

99 targeting DNAJC24, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-8062	99.88	68.43	995
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-8076	99.78	68.52	1170
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-8084	99.73	69.57	1760
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-30B-3P	99.70	65.76	2325

Literature-anchored findings (GeneRIF, showing 3)

• We report here the solution structure and mechanism of novel iron-mediated functional roles of human Dph4, a type III J-protein playing a vital role in diphthamide biosynthesis and normal development. (PMID:22367199)
• immunotoxin resistance is associated with reversible CpG island methylation and silencing of DPH4 gene transcription (PMID:22509046)
• DNAJC24 acts directly with PCNA and promotes malignant progression of LUAD by activating phosphorylation of AKT. (PMID:38713100)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio	dnajc24	ENSDARG00000023927
mus_musculus	Dnajc24	ENSMUSG00000027166
rattus_norvegicus	Dnajc24	ENSRNOG00000004842
drosophila_melanogaster	CG10565	FBGN0037051
drosophila_melanogaster	P58IPK	FBGN0037718
drosophila_melanogaster	l(3)80Fg	FBGN0287183
caenorhabditis_elegans		WBGENE00001020
caenorhabditis_elegans		WBGENE00001025
caenorhabditis_elegans		WBGENE00001026
caenorhabditis_elegans		WBGENE00001029
caenorhabditis_elegans	dnj-28	WBGENE00001046
caenorhabditis_elegans		WBGENE00008122

Paralogs (20): DNAJC11 (ENSG00000007923), DNAJC25 (ENSG00000059769), DNAJC10 (ENSG00000077232), DNAJC5 (ENSG00000101152), DNAJC3 (ENSG00000102580), DNAJC17 (ENSG00000104129), DNAJC2 (ENSG00000105821), DNAJC12 (ENSG00000108176), DNAJC4 (ENSG00000110011), DNAJC16 (ENSG00000116138), DNAJC14 (ENSG00000135392), DNAJC1 (ENSG00000136770), DNAJC13 (ENSG00000138246), DNAJC5B (ENSG00000147570), DNAJC5G (ENSG00000163793), DNAJC7 (ENSG00000168259), DNAJC21 (ENSG00000168724), DNAJC18 (ENSG00000170464), DNAJC30 (ENSG00000176410), DNAJC9 (ENSG00000213551)

Protein

Protein identifiers

DnaJ homolog subfamily C member 24 — Q6P3W2 (reviewed: Q6P3W2)

Alternative names: CSL-type zinc finger-containing protein 3, Diphthamide biosynthesis protein 4

All UniProt accessions (5): E9PID3, E9PRW3, Q6P3W2, H0YCV1, J3KPT8

UniProt curated annotations — full annotation on UniProt →

Function. Stimulates the ATPase activity of several Hsp70-type chaperones. This ability is enhanced by iron-binding. The iron-bound form is redox-active and can function as electron carrier. Plays a role in the diphthamide biosynthesis, a post-translational modification of histidine which occurs in translation elongation factor 2 (EEF2) which can be ADP-ribosylated by diphtheria toxin and by Pseudomonas exotoxin A (Eta).

Subunit / interactions. Monomer and homooligomer. Iron binding promotes oligomerization.

Subcellular location. Cytoplasm. Cytoskeleton.

Domain organisation. The DPH-type metal-binding (MB) domain can bind either zinc or iron ions.

Pathway. Protein modification; peptidyl-diphthamide biosynthesis.

Similarity. Belongs to the DPH4 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6P3W2-1	1	yes
Q6P3W2-2	2

RefSeq proteins (1): NP_859057* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001623	DnaJ_domain	Domain
IPR007872	DPH_MB_dom	Domain
IPR036671	DPH_MB_sf	Homologous_superfamily
IPR036869	J_dom_sf	Homologous_superfamily

Pfam: PF00226, PF05207

UniProt features (27 total): strand 9, helix 5, binding site 4, turn 3, domain 2, chain 1, splice variant 1, sequence variant 1, mutagenesis site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2L6L	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6P3W2-F1	74.66	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 115; 117; 136; 139

Mutagenesis-validated functional residues (1):

Position	Phenotype
139	loss of iron-binding.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-5358493	Synthesis of diphthamide-EEF2

MSigDB gene sets: 111 (showing top): AMIT_EGF_RESPONSE_60_HELA, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, BROWNE_HCMV_INFECTION_16HR_UP, PUJANA_CHEK2_PCC_NETWORK, GOBP_PROTEIN_MATURATION, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_PROTEIN_FOLDING, GOBP_REGULATION_OF_ATP_DEPENDENT_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_ATP_DEPENDENT_ACTIVITY, SCGGAAGY_ELK1_02, GOMF_ATPASE_ACTIVATOR_ACTIVITY, GOMF_ATPASE_REGULATOR_ACTIVITY, GOMF_FERROUS_IRON_BINDING, GOMF_IRON_ION_BINDING, PUIFFE_INVASION_INHIBITED_BY_ASCITES_DN

GO Biological Process (3): protein folding (GO:0006457), protein histidyl modification to diphthamide (GO:0017183), positive regulation of ATP-dependent activity (GO:0032781)

GO Molecular Function (4): ATPase activator activity (GO:0001671), ferrous iron binding (GO:0008198), zinc ion binding (GO:0008270), metal ion binding (GO:0046872)

GO Cellular Component (4): actin cytoskeleton (GO:0015629), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ATP-dependent activity	2
cellular anatomical structure	2
cellular process	1
protein maturation	1
peptidyl-histidine modification	1
regulation of ATP-dependent activity	1
positive regulation of molecular function	1
molecular function activator activity	1
iron ion binding	1
transition metal ion binding	1
cation binding	1
cytoskeleton	1
intracellular anatomical structure	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

2245 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DNAJC24	DCDC1	P59894	932
DNAJC24	IMMP1L	Q96LU5	923
DNAJC24	ELP4	Q96EB1	915
DNAJC24	DPH2	Q9BQC3	888
DNAJC24	MPPED2	Q15777	888
DNAJC24	DPH3	Q96FX2	887
DNAJC24	DPH1	Q9BZG8	843
DNAJC24	DPH5	Q9H2P9	810
DNAJC24	DPH7	Q9BTV6	804
DNAJC24	EEF2	P13639	782
DNAJC24	DPH6	Q7L8W6	747
DNAJC24	DNAJC21	Q5F1R6	669
DNAJC24	PAX6	P26367	655
DNAJC24	DNAJC28	Q9NX36	610
DNAJC24	DNAJC2	Q99543	557

IntAct

2 interactions, top by confidence:

A	B	Type	Score
DNAJC24	DNAJA2	psi-mi:“MI:0914”(association)	0.350

BioGRID (12): DNAJC24 (Biochemical Activity), DNAJC24 (Affinity Capture-MS), DNAJC24 (Positive Genetic), DPH2 (Affinity Capture-MS), CAPRIN1 (Affinity Capture-MS), DPH1 (Proximity Label-MS), DPH2 (Proximity Label-MS), DNAJA2 (Affinity Capture-MS), NUP88 (Affinity Capture-MS), ASPSCR1 (Affinity Capture-MS), DNAJC24 (Affinity Capture-MS), DNAJC24 (Affinity Capture-RNA)

ESM2 similar proteins: A7A283, A7SBN6, B3LUQ4, B5VI68, C4PYP8, C5E4V9, C7GYE7, C8Z7X8, E5KGE0, O13648, O13747, O13827, O14045, O43038, O59709, O74840, O94393, O94536, P12689, P25301, P32849, P35875, P36113, P38748, P43615, P47138, P87143, P87231, Q04149, Q04638, Q08930, Q0VBY7, Q10313, Q12347, Q54CI5, Q5AD49, Q6BPC1, Q6C6T1, Q6CUQ9, Q6FWM1

Diamond homologs: A0A0P0VG31, A0AIS3, A3N3J9, A4XKA5, A5F362, A5FZ18, A5UF67, A5WBF8, A6LRN5, A7GT07, A7I2G3, A7MWW1, A9IGC5, B0B7R0, B0BBX5, B0BTI6, B0UWR3, B2TLZ8, B2V2I6, B6IVA5, B7HCT9, B7IYG6, B8D757, B8D8V3, B8F7S3, B8I304, B9KH92, C3LTA6, C4L424, C5B7L8, O32465, O34136, O34242, O52065, O66921, O84345, P0CW06, P0CW07, P25303, P28616

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

36 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	2
Uncertain significance	19
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
1072681	NC_000011.9:g.(?31284590)(31824402_?)del	Pathogenic
647471	NC_000011.9:g.(?31284590)(31832374_?)del	Pathogenic
686012	GRCh37/hg19 11p13(chr11:31416012-31822354)x1	Pathogenic
1340711	GRCh37/hg19 11p13(chr11:31415634-31790329)x1	Likely pathogenic
545141	NC_000011.10:g.(?31405793)(31548667_?)del	Likely pathogenic

SpliceAI

1853 predictions. Top by Δscore:

Variant	Effect	Δscore
11:31369908:GTTAG:G	donor_gain	1.0000
11:31369909:T:G	donor_gain	1.0000
11:31370715:GCTA:G	acceptor_gain	1.0000
11:31370859:GGTA:G	donor_loss	1.0000
11:31370861:T:G	donor_loss	1.0000
11:31426285:A:AG	acceptor_gain	1.0000
11:31426286:G:GG	acceptor_gain	1.0000
11:31426286:GAA:G	acceptor_gain	1.0000
11:31429568:A:T	donor_gain	1.0000
11:31429599:GAGCC:G	donor_gain	1.0000
11:31429601:GCC:G	donor_gain	1.0000
11:31429603:C:CG	donor_gain	1.0000
11:31429603:C:G	donor_gain	1.0000
11:31369912:GGTA:G	donor_loss	0.9900
11:31369913:G:GG	donor_gain	0.9900
11:31369913:GTA:G	donor_loss	0.9900
11:31369914:T:G	donor_loss	0.9900
11:31370714:A:AG	acceptor_gain	0.9900
11:31370715:G:GA	acceptor_gain	0.9900
11:31370715:GCT:G	acceptor_gain	0.9900
11:31370860:G:GG	donor_gain	0.9900
11:31370862:AA:A	donor_loss	0.9900
11:31414809:A:AG	acceptor_gain	0.9900
11:31414810:G:GG	acceptor_gain	0.9900
11:31414927:A:T	donor_gain	0.9900
11:31426279:TTTTA:T	acceptor_loss	0.9900
11:31426280:TTTAC:T	acceptor_loss	0.9900
11:31426281:TTACA:T	acceptor_loss	0.9900
11:31426282:TACA:T	acceptor_loss	0.9900
11:31426283:ACAG:A	acceptor_loss	0.9900

AlphaMissense

989 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:31414814:C:G	H39D	0.992
11:31414892:G:C	A65P	0.984
11:31414816:T:A	H39Q	0.982
11:31414816:T:G	H39Q	0.982
11:31414874:T:C	F59L	0.980
11:31414876:C:A	F59L	0.980
11:31414876:C:G	F59L	0.980
11:31414825:A:C	K42N	0.979
11:31414825:A:T	K42N	0.979
11:31414893:C:A	A65E	0.976
11:31370832:A:C	K28N	0.972
11:31370832:A:T	K28N	0.972
11:31370839:T:G	Y31D	0.972
11:31430300:T:A	C117S	0.970
11:31430301:G:C	C117S	0.970
11:31414814:C:A	H39N	0.968
11:31414905:T:A	L69Q	0.965
11:31414895:T:A	W66R	0.963
11:31414895:T:C	W66R	0.963
11:31430312:T:G	Y121D	0.963
11:31430357:T:A	C136S	0.957
11:31430358:G:A	C136Y	0.957
11:31430358:G:C	C136S	0.957
11:31430300:T:C	C117R	0.956
11:31430294:T:A	C115S	0.955
11:31430295:G:C	C115S	0.955
11:31430294:T:C	C115R	0.954
11:31430313:A:C	Y121S	0.954
11:31414924:A:C	K75N	0.952
11:31414924:A:T	K75N	0.952

dbSNP variants (sampled 300 via entrez): RS1000028266 (11:31410022 T>A,C), RS1000072464 (11:31429302 T>A,C), RS1000099716 (11:31390478 G>A), RS1000101524 (11:31410368 T>C), RS1000142609 (11:31385525 C>G), RS1000152429 (11:31385802 G>A), RS1000154681 (11:31383959 A>G), RS1000167669 (11:31431668 A>G), RS1000177592 (11:31396914 A>C), RS1000202503 (11:31399347 G>A), RS1000265286 (11:31389734 A>G), RS1000294106 (11:31421534 A>G,T), RS1000344172 (11:31424042 G>A), RS1000348748 (11:31402625 C>T), RS1000401802 (11:31379477 C>T)

Disease associations

OMIM: gene MIM:611072 | disease phenotypes: MIM:604229, MIM:106210, MIM:181500

GenCC curated gene-disease

Mondo (3): Peters anomaly (MONDO:0011414), aniridia 1 (MONDO:0024507), schizophrenia (MONDO:0005090)

Orphanet (3): Isolated aniridia (Orphanet:250923), Peters anomaly (Orphanet:708), NON RARE IN EUROPE: Schizophrenia (Orphanet:3140)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0000659	Peters anomaly
HP:0100753	Schizophrenia

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST002529_6	Glaucoma	8.000000e-09
GCST004601_155	Red blood cell count	9.000000e-13
GCST008058_101	Estimated glomerular filtration rate	9.000000e-19
GCST008059_79	Estimated glomerular filtration rate	8.000000e-21
GCST010703_25	Brain morphology (MOSTest)	2.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004305	erythrocyte count
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C537884	Peters anomaly (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, decreases expression	3
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
perfluorohexanesulfonic acid	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	increases expression, affects cotreatment, increases abundance	1
Atrazine	increases expression	1
Dimethyl Sulfoxide	increases expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1
Urethane	increases expression	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	increases expression	1
Copper Sulfate	increases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety